{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:51:08Z","timestamp":1792439468556,"version":"4.5.0"},"reference-count":34,"publisher":"American Diabetes Association","issue":"5","license":[{"start":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T00:00:00Z","timestamp":1492646400000},"content-version":"vor","delay-in-days":38,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,5,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To assess the efficacy and safety of coadministration of canagliflozin (CANA) and phentermine (PHEN) compared with placebo (PBO) and CANA or PHEN monotherapies in individuals who were overweight and obese without type 2 diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>This 26-week, phase 2a, randomized, double-blind, PBO-controlled, multicenter, parallel-group study enrolled individuals who were obese or overweight without type 2 diabetes (N = 335, aged 18\u201365 years, BMI \u226530 to &amp;lt;50 kg\/m2 or BMI \u226527 to &amp;lt;50 kg\/m2 with hypertension and\/or dyslipidemia). Participants were randomized (1:1:1:1) to receive PBO, CANA 300 mg, PHEN 15 mg, or coadministration of CANA 300 mg and PHEN 15 mg (CANA\/PHEN) orally once daily. The primary end point was percent change in body weight from baseline to week 26; key secondary end points were the proportion of participants achieving weight loss \u22655% and change from baseline in systolic blood pressure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>CANA\/PHEN provided statistically superior weight loss from baseline versus PBO at week 26 (least squares mean difference \u20136.9% [95% CI \u20138.6 to \u20135.2]; P &amp;lt; 0.001). CANA\/PHEN also provided statistically superior achievement of weight loss \u22655% and reduction in systolic blood pressure compared with PBO. CANA\/PHEN was generally well tolerated, with a safety and tolerability profile consistent with that of the individual components.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>CANA\/PHEN produced meaningful reductions in body weight and was generally well tolerated in individuals who were overweight or obese without type 2 diabetes. Further studies are warranted to evaluate potential use of this combination for long-term weight management.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc16-2427","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T00:37:43Z","timestamp":1489451863000},"page":"632-639","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":97,"title":["Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial"],"prefix":"10.2337","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2072-632X","authenticated-orcid":false,"given":"Priscilla","family":"Hollander","sequence":"first","affiliation":[{"name":"Baylor University Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold E.","family":"Bays","sequence":"additional","affiliation":[{"name":"Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-3275","authenticated-orcid":false,"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"Dallas Diabetes Research Center at Medical City, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ellen","family":"Frustaci","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Fung","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Vercruysse","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngozi","family":"Erondu","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2017,3,13]]},"reference":[{"key":"2022031301433114100_B1","unstructured":"American Medical Association House of Delegates. Resolution 420 (A-13). Recognition of obesity as a disease [Internet], 2013. Available from http:\/\/www.ama-assn.org\/assets\/meeting\/2013a\/a13-addendum-refcomm-d.pdf. Accessed 14 November 2016"},{"key":"2022031301433114100_B2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jacl.2013.04.001","article-title":"Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association","volume":"7","author":"Bays","year":"2013","journal-title":"J Clin Lipidol"},{"key":"2022031301433114100_B3","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1161\/01.CIR.0000145546.97738.1E","article-title":"Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation","volume":"110","author":"Klein","year":"2004","journal-title":"Circulation"},{"key":"2022031301433114100_B4","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1161\/01.cir.0000437739.71477.ee","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"2022031301433114100_B5","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/sj.ijo.0802982","article-title":"Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice","volume":"29","author":"Douketis","year":"2005","journal-title":"Int J Obes"},{"key":"2022031301433114100_B6","unstructured":"U.S. Food and Drug Administration. Guidance for industry: developing products for weight management [Internet], 2007. Available from http:\/\/www.fda.gov\/downloads\/Drugs\/...\/Guidances\/ucm071612.pdf. Accessed 14 November 2016"},{"key":"2022031301433114100_B7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"2022031301433114100_B8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"2022031301433114100_B9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an Endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031301433114100_B10","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.2337\/dc14-0930","article-title":"Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031301433114100_B11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","article-title":"Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects","volume":"13","author":"Sha","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031301433114100_B12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1463-1326.2012.01558.x","article-title":"Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin","volume":"14","author":"Devineni","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2022031301433114100_B13","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/oby.20663","article-title":"Canagliflozin: effects in overweight and obese subjects without diabetes mellitus","volume":"22","author":"Bays","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"2022031301433114100_B14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/nyas.12852","article-title":"Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus","volume":"1358","author":"Rosenthal","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"2022031301433114100_B15","first-page":"183","article-title":"Canagliflozin for the treatment of adults with type 2 diabetes","volume":"5","author":"Meininger","year":"2015"},{"key":"2022031301433114100_B16","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstr\u00e5le","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031301433114100_B17","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031301433114100_B18","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/dc15-0355","article-title":"Energy balance after sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Ferrannini","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031301433114100_B19","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2337\/db10-1328","article-title":"SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function","volume":"60","author":"Jurczak","year":"2011","journal-title":"Diabetes"},{"key":"2022031301433114100_B20","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/oby.2012.59","article-title":"Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats","volume":"20","author":"Devenny","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"2022031301433114100_B21","doi-asserted-by":"crossref","unstructured":"Polidori D, Sanghvi A, Seeley R, Hall KD. How strongly does appetite counter weight loss? Quantification of the homeostatic control of human energy intake. Obesity (Silver Spring) 2016;24:2289\u20132295","DOI":"10.1002\/oby.21653"},{"key":"2022031301433114100_B22"},{"key":"2022031301433114100_B23"},{"key":"2022031301433114100_B24"},{"key":"2022031301433114100_B25"},{"key":"2022031301433114100_B26"},{"key":"2022031301433114100_B27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/dom.12502","article-title":"Current and emerging medications for overweight or obesity in people with comorbidities","volume":"17","author":"Fujioka","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2022031301433114100_B28","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"2022031301433114100_B29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031301433114100_B30","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"2022031301433114100_B31","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0140-6736(11)60812-X","article-title":"Quantification of the effect of energy imbalance on bodyweight","volume":"378","author":"Hall","year":"2011","journal-title":"Lancet"},{"key":"2022031301433114100_B32","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"2022031301433114100_B33","first-page":"S313","article-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces body weight mainly through loss of fat mass in subjects with type 2 diabetes","volume":"55","author":"Toubro","year":"2012","journal-title":"Diabetologia"},{"key":"2022031301433114100_B34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/00325481.2016.1169894","article-title":"Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks","volume":"128","author":"Blonde","year":"2016","journal-title":"Postgrad Med"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc16-2427","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/5\/632\/549232\/dc162427.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/5\/632\/549232\/dc162427.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T05:41:42Z","timestamp":1647150102000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/40\/5\/632\/36777\/Coadministration-of-Canagliflozin-and-Phentermine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,13]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,3,13]]},"published-print":{"date-parts":[[2017,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc16-2427","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,13]]}}}